

Cover Story
Clinical
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- As cancer research is threatened, we must engage in political advocacy
- “The Agency finds you are not fit…”
HHS notifications of firing add insult to injury - Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”